Your browser doesn't support javascript.
loading
Patient and Kidney Allograft Survival in Recipients With End-Stage Renal Disease From Amyloidosis.
Sawinski, Deirdre; Lim, Mary Ann; Cohen, Jordana B; Locke, Jayme E; Weiss, Brendan; Hogan, Jonathan J; Dember, Laura M.
Afiliação
  • Sawinski D; Renal, Electrolyte and Hypertension Division, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA.
  • Lim MA; Renal, Electrolyte and Hypertension Division, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA.
  • Cohen JB; Renal, Electrolyte and Hypertension Division, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA.
  • Locke JE; Center for Clinical Epidemiology and Biostatistics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA.
  • Weiss B; Comprehensive Transplant Institute, University of Alabama at Birmingham, Birmingham, AL.
  • Hogan JJ; Penn Amyloidosis Program, Division of Hematology-Oncology, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA.
  • Dember LM; Division of Hematology/Oncology, Hospital of the University of Pennsylvania, Philadelphia, PA.
Transplantation ; 102(2): 300-309, 2018 02.
Article em En | MEDLINE | ID: mdl-28885498
BACKGROUND: Outcomes after kidney transplantation for patients with amyloidosis-associated end-stage renal disease (ESRD) have not been well characterized. METHODS: We performed a retrospective propensity score matched cohort study with Cox proportional hazards modeling using data from the United Network of Organ Sharing including patients transplanted from 1987 to 2015 (N = 310 629). RESULTS: Amyloidosis patients (N = 576) had higher rates of death (hazard ratio [HR], 1.58; 95% confidence interval [CI], 1.28-1.95) and graft loss (HR, 1.49; 95% CI, 1.19-1.87) compared with nonamyloidosis patients. The results were similar when the cohort was restricted to patients transplanted on or after 2001 (HR, 1.72; 95% CI, 1.31-2.26 for death; HR, 1.77; 95% CI, 1.35-2.33 for graft loss). However, there was no significant difference in risk of death or graft loss when amyloidosis patients were compared with those with diabetes-associated ESRD (mortality: HR, 0.99; 95% CI, 0.84-1.17; allograft loss: HR, 1.00; 95% CI, 0.84-1.20), or when compared with elderly patients (age, >65 years at the time of transplant) (mortality: HR, 0.99; 95% CI, 0.81-1.21; graft loss: HR, 1.02; 95% CI, 0.82-1.26). CONCLUSIONS: For patients with amyloidosis-associated ESRD deemed suitable for transplantation, patient and graft survivals are diminished compared to kidney transplant recipients overall, but are comparable to other high-risk subgroups.
Assuntos
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Transplante de Rim / Sobrevivência de Enxerto / Amiloidose / Falência Renal Crônica Tipo de estudo: Observational_studies / Prognostic_studies Limite: Adult / Female / Humans / Male / Middle aged Idioma: En Revista: Transplantation Ano de publicação: 2018 Tipo de documento: Article País de publicação: Estados Unidos
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Transplante de Rim / Sobrevivência de Enxerto / Amiloidose / Falência Renal Crônica Tipo de estudo: Observational_studies / Prognostic_studies Limite: Adult / Female / Humans / Male / Middle aged Idioma: En Revista: Transplantation Ano de publicação: 2018 Tipo de documento: Article País de publicação: Estados Unidos